OBJECTIVE: Natalizumab is a humanized recombinant monoclonal antibody against very late activation antigen-4 approved for the treatment of patients with multiple sclerosis (MS). A phase II study failed to demonstrate a difference between natalizumab treatment groups and the placebo group with regard to gadolinium enhancing lesions on MRI 3 months after discontinuation of therapy. The objective of this study was to assess clinical MS disease activity, surrogate disease markers on MRI, immunologic parameters in peripheral blood and CSF, as well as safety in patients with MS after discontinuation of natalizumab therapy. METHODS: This study is a longitudinal and serial cross-sectional assessment, in which 23 patients who were treated with natalizumab in the context of two phase III clinical trials were originally enrolled. A subgroup of patients was followed over 14 months. The annual relapse rate, neurologic disease progression assessed by the Expanded Disability Status Scale, disease surrogate markers on MRI, cellular and humoral immune markers in peripheral blood and CSF, and adverse events of the drug were monitored. RESULTS: With regard to clinical disease activity, neuroimaging, and immune responses, the majority of patients in our cohort were stable. Decreased lymphocyte cell numbers and altered cell ratios returned to normal 14 months after cessation of natalizumab. No infectious complications were observed. CONCLUSION: This is the first long-term follow-up of patients who discontinued natalizumab. We did not observe a clinical, radiographic, or immunologic rebound phenomenon after discontinuation of natalizumab therapy.
OBJECTIVE: Natalizumab is a humanized recombinant monoclonal antibody against very late activation antigen-4 approved for the treatment of patients with multiple sclerosis (MS). A phase II study failed to demonstrate a difference between natalizumab treatment groups and the placebo group with regard to gadolinium enhancing lesions on MRI 3 months after discontinuation of therapy. The objective of this study was to assess clinical MS disease activity, surrogate disease markers on MRI, immunologic parameters in peripheral blood and CSF, as well as safety in patients with MS after discontinuation of natalizumab therapy. METHODS: This study is a longitudinal and serial cross-sectional assessment, in which 23 patients who were treated with natalizumab in the context of two phase III clinical trials were originally enrolled. A subgroup of patients was followed over 14 months. The annual relapse rate, neurologic disease progression assessed by the Expanded Disability Status Scale, disease surrogate markers on MRI, cellular and humoral immune markers in peripheral blood and CSF, and adverse events of the drug were monitored. RESULTS: With regard to clinical disease activity, neuroimaging, and immune responses, the majority of patients in our cohort were stable. Decreased lymphocyte cell numbers and altered cell ratios returned to normal 14 months after cessation of natalizumab. No infectious complications were observed. CONCLUSION: This is the first long-term follow-up of patients who discontinued natalizumab. We did not observe a clinical, radiographic, or immunologic rebound phenomenon after discontinuation of natalizumab therapy.
Authors: Olaf Stüve; Christina M Marra; Keith R Jerome; Linda Cook; Petra D Cravens; Sabine Cepok; Elliot M Frohman; J Theodore Phillips; Gabriele Arendt; Bernhard Hemmer; Nancy L Monson; Michael K Racke Journal: Ann Neurol Date: 2006-05 Impact factor: 10.422
Authors: Annette Langer-Gould; Scott W Atlas; Ari J Green; Andrew W Bollen; Daniel Pelletier Journal: N Engl J Med Date: 2005-06-09 Impact factor: 91.245
Authors: Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts Journal: N Engl J Med Date: 2005-06-09 Impact factor: 91.245
Authors: Olaf Stüve; Christina M Marra; Amit Bar-Or; Masaaki Niino; Petra D Cravens; Sabine Cepok; Elliot M Frohman; J Theodore Phillips; Gabriele Arendt; Keith R Jerome; Linda Cook; Francois Grand'Maison; Bernhard Hemmer; Nancy L Monson; Michael K Racke Journal: Arch Neurol Date: 2006-10
Authors: Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock Journal: N Engl J Med Date: 2006-03-02 Impact factor: 91.245
Authors: Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock Journal: N Engl J Med Date: 2006-03-02 Impact factor: 91.245
Authors: David H Miller; Omar A Khan; William A Sheremata; Lance D Blumhardt; George P A Rice; Michele A Libonati; Allison J Willmer-Hulme; Catherine M Dalton; Katherine A Miszkiel; Paul W O'Connor Journal: N Engl J Med Date: 2003-01-02 Impact factor: 91.245
Authors: Martin Stangel; Sten Fredrikson; Edgar Meinl; Axel Petzold; Olaf Stüve; Hayrettin Tumani Journal: Nat Rev Neurol Date: 2013-03-26 Impact factor: 42.937
Authors: Vilija G Jokubaitis; Vivien Li; Tomas Kalincik; Guillermo Izquierdo; Suzanne Hodgkinson; Raed Alroughani; Jeannette Lechner-Scott; Alessandra Lugaresi; Pierre Duquette; Marc Girard; Michael Barnett; Francois Grand'Maison; Maria Trojano; Mark Slee; Giorgio Giuliani; Cameron Shaw; Cavit Boz; Daniele L A Spitaleri; Freek Verheul; Jodi Haartsen; Danny Liew; Helmut Butzkueven Journal: Neurology Date: 2014-03-07 Impact factor: 9.910
Authors: A Ghezzi; L M E Grimaldi; M G Marrosu; C Pozzilli; G Comi; A Bertolotto; M Trojano; P Gallo; R Capra; D Centonze; E Millefiorini; S Sotgiu; V Brescia Morra; M P Amato; A Lugaresi; G Mancardi; D Caputo; E Montanari; L Provinciali; L Durelli; R Bergamaschi; P Bellantonio; M R Tola; S Cottone; G Savettieri; G Tedeschi Journal: Neurol Sci Date: 2011-04 Impact factor: 3.307